Want to see HK:0575 full AI Analyst Report?
Top Page
Endurance RP
(0575)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.82
▼(-14.00% Downside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance—ongoing losses, volatile revenue, persistent cash burn, and negative equity. Technicals provide some support due to strong price strength above key moving averages and positive MACD, but the very high RSI suggests momentum may be stretched. Valuation is not supportive given the negative P/E (loss-making) and no indicated dividend yield.
Positive Factors
High gross margin
A very high gross margin indicates the company can retain substantial revenue after direct costs, creating potential operating leverage if sales stabilize. However, the benefit is not yet durable because historical margins have varied and have not translated into positive EBIT, EBITDA, or net income.
Negative Factors
Persistent losses and volatile revenue
Deepening losses combined with sharply volatile revenue make earnings quality and forward planning difficult. The weak top line is not currently supporting operating leverage, while negative EBIT and EBITDA indicate that the company lacks a stable profit engine capable of converting demand into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A very high gross margin indicates the company can retain substantial revenue after direct costs, creating potential operating leverage if sales stabilize. However, the benefit is not yet durable because historical margins have varied and have not translated into positive EBIT, EBITDA, or net income.
Read all positive factors
Endurance RP (0575) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$240.75M
Dividend Yield87.25%
Average Volume (3M)39.85K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth496.98%
EPS Growth62.36%
CountryHK
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding291,815,800
10 Day Avg. Volume31,295
30 Day Avg. Volume39,846
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)-5.41
Price to Sales (P/S)98.99
P/FCF Ratio-8.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Endurance RP Business Overview & Revenue Model
Company Description
Regent Pacific Group Limited is an investment holding company that primarily focuses on the healthcare and life sciences sectors. The company is involved in the research, development, and sale of pharmaceutical products, with a notable focus on tr...
Endurance RP Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
11
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.42M | 363.00K | 719.00K | 382.00K | 114.00K | 3.25M |
| Gross Profit | 5.02M | -420.00K | -219.00K | -2.34M | -1.11M | 850.00K |
| EBITDA | -896.33K | -4.29M | 18.01M | -7.72M | -9.56M | 10.38M |
| Net Income | -1.95M | -4.71M | -4.48M | -25.05M | -36.43M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 5.73M | 570.92K | 610.00K | 2.79M | 26.32M | 62.23M |
| Cash, Cash Equivalents and Short-Term Investments | 255.96K | 187.97K | 121.00K | 2.42M | 1.41M | 11.13M |
| Total Debt | 7.36M | 3.94M | 3.34M | 1.20M | 13.73M | 14.01M |
| Total Liabilities | 11.78M | 7.21M | 6.51M | 4.35M | 23.72M | 23.46M |
| Stockholders Equity | -6.05M | -6.64M | -5.90M | -1.55M | 2.60M | 38.77M |
Cash Flow | ||||||
| Free Cash Flow | -2.14M | -4.32M | -4.13M | -3.59M | 533.00K | -1.75M |
| Operating Cash Flow | -2.14M | -4.30M | -4.13M | -3.59M | 545.00K | -1.70M |
| Investing Cash Flow | -1.01K | -15.02K | -3.00K | -1.00K | -7.00K | 123.00K |
| Financing Cash Flow | 2.14M | 4.35M | 2.14M | 5.58M | -795.00K | -782.00K |
Endurance RP Technical Analysis
Negative
0.95
Price Trends
0.92
Negative
0.81
Positive
0.86
Negative
Market Momentum
-0.02
Positive
31.26
Neutral
17.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0575, the sentiment is Negative. The current price of 0.95 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.92, and above the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.26 is Neutral, neither overbought nor oversold. The STOCH value of 17.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0575.
Endurance RP Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$128.02M | -4.55 | -4.90% | ― | -126.01% | -237.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$690.03M | -18.88 | -13.47% | 1.45% | 50.81% | -327.36% | |
48 Neutral | HK$240.75M | -15.51 | 30.76% | 87.25% | 496.98% | 62.36% | |
46 Neutral | HK$252.87M | -0.14 | -16.70% | 2.91% | 163.09% | 52.42% | |
44 Neutral | HK$298.08M | -40.83 | -66.95% | ― | ― | -700.00% | |
41 Neutral | HK$69.57M | -5.46 | -82.36% | 13.54% | ― | 79.32% |
* Healthcare Sector Average
HK:0575
Endurance RP
0.82
0.08
11.64%
HK:0129
Asia Standard International Group
0.18
-0.15
-45.23%
HK:1217
China Innovation Investment Limited
0.01
>-0.01
-33.33%
HK:1835
Shanghai Realway Capital Assets Management Co., Ltd. Class H
4.50
2.30
104.55%
HK:0310
Prosperity Investment Holdings Limited
0.11
0.01
12.00%
HK:0339
Core Economy Investment Group Limited
0.69
0.50
255.67%
Endurance RP Corporate Events
Regent Pacific Secures Milestone Payment as Fosun Readies Senstend Launch in China
Sep 1, 2026
Regent Pacific Group has received a US$4.5 million milestone payment from Fosun Wanbang (Jiangsu) Pharmaceutical Group under their licensing and collaboration agreement for Senstend™ in mainland China, reinforcing the strength of their strat...
Endurance RP lifts profit on China milestone as telehealth and Fortacin™ expansion advance
Aug 25, 2026
Endurance RP reported an unaudited profit of about US$544,000 for the six months to 30 June 2026, driven primarily by a US$5 million milestone from Fosun Wanbang following Chinese approval of Senstend™, partially offset by impairment charges...
Regent Pacific Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 13, 2026
Regent Pacific Group Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their release to the market. The board will also consider whether to declare ...
Regent Pacific Signals Return to Profit on Senstend Milestone Payment
Aug 3, 2026
Regent Pacific Group Limited has issued a positive profit alert, indicating it expects to post a net profit of between US$0.5 million and US$1 million for the six months ended 30 June 2026, versus a loss of about US$2.22 million a year earlier. Ma...
Regent Pacific Clarifies One-Off Reimbursement Behind Drop in 2025 Receivables
Jul 9, 2026
Regent Pacific Group Limited has clarified movements in its balance sheet, noting that prepayments, deposits and other receivables fell about 22.76% to US$285,000 as of 31 December 2025 from US$369,000 a year earlier. The company attributed this d...
Deep Longevity’s Blood-Based Age Model Shown to Predict Mortality and Hospitalization Risk
Jun 30, 2026
A near decade-long study of 2,597 adults, published in the journal Aging and Disease, has validated Deep Longevity’s BloodAge model as a significant predictor of mortality and hospitalization risk. Using 36 standard blood biomarkers, the mod...
Deep Longevity wins global recognition in Nestlé smart aging challenge
Jun 25, 2026
Deep Longevity, an AI-driven biological aging intelligence company owned by Regent Pacific Group, has been named runner-up in the Nestlé VITAL Smart Aging Global Challenge, a competition that attracted 150 health technology firms worldwide. T...
Endurance RP Wins Landmark China Approval for Senstend, Triggering Milestones and Global Push
Jun 16, 2026
Endurance RP has secured Chinese National Medical Products Administration approval for its premature ejaculation spray Senstend, marking its transition into a commercial-stage biopharmaceutical player. The drug is only the second NMPA-approved the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.